Article
Flotetuzumab (FLZ), an Investigational CD123 x CD3 Bispecific Dart® Protein-Induced Clustering of CD3+ T Cells and CD123+ AML Cells in Bone Marrow Biopsies Is Associated with Response to Treatment in Primary Refractory AML Patients
Blood
(2019)
Disciplines
Publication Date
November 13, 2019
DOI
10.1182/BLOOD-2019-128485
Citation Information
John E. Godwin, Carmen Ballesteros-Merino, Nikhil Lonberg, Shawn Jensen, et al.. "Flotetuzumab (FLZ), an Investigational CD123 x CD3 Bispecific Dart® Protein-Induced Clustering of CD3+ T Cells and CD123+ AML Cells in Bone Marrow Biopsies Is Associated with Response to Treatment in Primary Refractory AML Patients" Blood Vol. 134 (2019) p. 1410 - 1410 Available at: http://works.bepress.com/carlo-bifulco/60/